-
Canaccord Genuity Starts Mesoblast Limited (MSB:AU) (MESO) at Buy
-
Jefferies Downgrades Mesoblast Limited (MSB:AU) (MESO) to Hold
-
Mesoblast Limited (MSB) received seven years of orphan-drug exclusive approval from US FDA
-
Jefferies Downgrades Mesoblast Limited (MSB:AU) (MESO) to Hold
-
Mesoblast Limited (MESO) PT Raised to $15 at Piper Sandler as FDA Approves Ryoncil
-
FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease
-
Mesoblast (MESO) Added to Nasdaq Biotechnology Index
-
Piper Sandler Reiterates Overweight Rating on Mesoblast Limited (MESO)
-
Mesoblast (MESO) Reports FY Loss of $0.09
-
Jefferies Upgrades Mesoblast Limited (MSB:AU) (MESO) to Buy
-
Mesoblast Limited (MESO): FDA Accepts BLA for Ryoncil in Children With Steroid-Refractory Acute Graft-Versus-Host Disease

